ESTRO PT 2018

“Lessons learned” from MGH/MDACC Phase III NSCLC trial

➢ peer review of contours is critical;

➢ image guidance with daily kV imaging and weekly CT scans is very important;

➢ modifications to treatment plans to adapt to changes in tumor or anatomy were needed in 20% of IMRT cases and 55% of proton cases*

➢ ~ 70% of all patients could be randomized, and among the randomized patients, 75% were at 74 Gy (RBE) and 25% at 66 Gy (RBE) dose levels; ➢ the rate of treatment interruption or incompletion has been extremely low.